Register Now - Every Drop Matters: Reducing Product Loss in Sterile Filtration
|Articles|March 1, 2011

BioPharm International

  • BioPharm International-03-01-2011
  • Volume 24
  • Issue 3

Change and Innovation

Author(s)Allen Basis

BioPharm International is the longest-running peer-reviewed publication dedicated to your work.

Recently we announced the appointment of Michelle Hoffman as Editorial Director of Advanstar's Pharmaceutical Drug Development and Manufacturing Group, which now includes BioPharm International, Pharmaceutical Technology, Pharmaceutical Technology Europe, and the IVT Journals. I am pleased to join Ms. Hoffman as BioPharm International's new publisher.

Allen Basis

It is exciting to work with an editor whose curriculum vita matches our tagline, "The Science & Business of Pharmaceuticals." Michelle's appointment and my employment and dedication to BioPharm International are examples of an evolving list of investments Advanstar Communications, our parent, is making in the brand. With more than 20 years of media management, I am dedicated to developing new and innovative ways of delivering the content you've come to depend on in print and online.

BioPharm International is the longest-running peer-reviewed publication dedicated to facilitating your work in the development and manufacturing of biotherapeutics and managing related business issues. Our goal is to provide the most up-to-date, reliable, and insightful information available to you in the biopharmaceutical market. To ensure that we meet your needs, I will seek your opinions about our performance.

We strive to equip you to manage your technical and business challenges effectively, but if we can serve you better with more news and information on tools, techniques, or business, we invite you to please let us know. Please drop us a line and be sure to look for us at industry conferences and expos throughout the year.

All the best,

Allen Basis is the publisher of BioPharm International, abasis@advanstar.com.

Related to this article

The BioPharm Brief: A Matrix-Targeting ADC in Head and Neck Cancer, an RNAi Approval in Myasthenia Gravis, and AbbVie Bets on AND-Gated Bispecifics
Pyxis Oncology’s EDB+FN-targeting ADC micvotabart pelidotin shows a 39% confirmed response rate in previously treated head and neck cancer, FDA approves Regeneron and Alnylam’s cemdisiran (Livsayis) as the first RNAi therapy for generalized myasthenia gravis, and AbbVie partners with DISCO Pharmaceuticals on AND-gated bispecifics for solid tumors.
The BioPharm Brief: A First for Streamlined Biosimilar Approval, a Head-to-Head Bispecific Trial in Wet AMD, and In Vivo KIR-CAR T
Biocon’s pertuzumab biosimilar Pebrilzo becomes the first biosimilar approved under EMA’s tailored clinical approach, Visara doses the first patient in a phase 2b trial comparing its VEGF-A/ANG-2 bispecific VIS-101 with aflibercept in wet AMD, and Verismo Therapeutics licenses Stanford’s PACK-IT technology for in vivo KIR-CAR T therapies.